Long-acting injectable treatment for HIV in Belgium

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to evaluate the patient-reported outcomes and clinical results of long-acting injectable cabotegravir/rilpivirine for HIV treatment. It will involve multiple centers and focus on assessing patient satisfaction and perceptions regarding this treatment. Participants will include HIV-1 patients who have received at least one dose of the medication between specified dates. The study will also collect demographic and health-related data to better understand the characteristics of the participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB/RPV between September 1, 2021, and March 31, 2024.

Where it's running

• Saint-Pierre University Hospital
  Brussels, Belgium Recruiting

Study contacts

• Principal investigator: Stéphane De Wit, MD/PhD — Belgian Research on AIDS & HIV Consortium
• Study coordinator: Rakan Nasreddine, MD
• Email: rakan.nasreddine@stpierre-bru.be
• Phone: +32 2 535 4130

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ICVAX therapeutic DNA vaccine for people living with HIV in Hong Kong

  This trial tests whether the ICVAX DNA vaccine, given with three different delivery devices, is safe and boosts HIV-specific T-cell responses in adults on stable antiretroviral therapy.

  Recruiting Phase 1 Yicura Holding (HK) Limited · Shatin, New Territories · NCT07530198

• Adding lenacapavir to ART to try to shrink hidden HIV reservoirs

  This study will test whether giving lenacapavir in addition to a stable ART regimen can reduce hidden HIV reservoirs in adults who have had undetectable viral loads for at least three years.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06819176

• SUSTAIN 2: Sustained HIV treatment support after interruptions in care

  This trial will test whether a six-month adherence club model with multi-month ART dispensing and peer support helps adults with HIV who missed care or have a raised viral load stay on treatment and reach viral suppression over 24 months.

  Recruiting Brigham and Women's Hospital · Cape Town · NCT06554223

• Universal Test and Connect for HIV services in Cape Town emergency departments

  This project tests whether offering universal HIV testing and connection-to-care in two Cape Town emergency departments can find people with HIV or at high risk and link them to treatment or PrEP.

  Recruiting Johns Hopkins University · Cape Town, Western Cape · NCT06408142

• Evaluating a new HIV vaccine combination in healthy adults

  This study is testing a new combination of HIV vaccines in healthy adults to see if they are safe and can help the body build protection against the virus.

  Recruiting Phase 1 U.S. Army Medical Research and Development Command · Kampala · NCT06205056

• Exploring the effects of gut microbiota on inflammation in people with HIV and alcohol use disorder

  This study tests whether taking prebiotics can help reduce inflammation and improve gut health in people with HIV who also struggle with alcohol use disorder.

  Recruiting Rush University Medical Center · Chicago, Illinois · NCT06139224

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.